Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection

Graeme Moyle, Jose Gatell, Carlo Federico Perno, Winai Ratanasuwan, Mauro Schechter, Christos Tsoukas

Research output: Contribution to journalArticle

Abstract

Despite the myriad advances in antiretroviral therapy since the original highly active antiretroviral therapy regimens were developed, there remain numerous important and pressing unmet needs that, if addressed, would substantially improve the quality of life and longevity of HIV-infected patients. The most achievable goals of antiretroviral (ARV) therapy in the near future are likely to be continued reduction in HIV-related morbidity and mortality; improved quality of life; and restoration and preservation of immune function: all of which are most effectively achieved through sustained suppression of HIV-1 RNA. The ability to achieve long-term viral load reduction will require new ARVs with few, manageable toxicities, and medications that are convenient to adhere to, with few drug interactions. This is particularly true for the large number of highly treatment-experienced patients in whom HIV has developed resistance to one or more ARVs. Development of therapies that allow convenient dosing schedules, that do not necessitate strict adherence to meal-related timing restrictions, and that remain active in the face of resistance mutations is paramount, and remains a significant unmet need. Of the large number of ARVs currently in development, this article focuses on three agents recently approved that have shown particular promise in addressing some of these unmet needs: the novel non-nucleoside reverse transcriptase inhibitor etravirine; the CCR5 antagonist maraviroc; and the integrase inhibitor raltegravir.

Original languageEnglish
Pages (from-to)459-471
Number of pages13
JournalAIDS Patient Care and STDs
Volume22
Issue number6
DOIs
Publication statusPublished - Jun 1 2008

Fingerprint

HIV Infections
HIV-1
etravirine
HIV
Integrase Inhibitors
Quality of Life
Reverse Transcriptase Inhibitors
Highly Active Antiretroviral Therapy
Therapeutics
Viral Load
Drug Interactions
Meals
Appointments and Schedules
RNA
Morbidity
Mutation
Mortality

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. / Moyle, Graeme; Gatell, Jose; Perno, Carlo Federico; Ratanasuwan, Winai; Schechter, Mauro; Tsoukas, Christos.

In: AIDS Patient Care and STDs, Vol. 22, No. 6, 01.06.2008, p. 459-471.

Research output: Contribution to journalArticle

Moyle, Graeme ; Gatell, Jose ; Perno, Carlo Federico ; Ratanasuwan, Winai ; Schechter, Mauro ; Tsoukas, Christos. / Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. In: AIDS Patient Care and STDs. 2008 ; Vol. 22, No. 6. pp. 459-471.
@article{4d5f518ad03b426d9fee8960cc463a9e,
title = "Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection",
abstract = "Despite the myriad advances in antiretroviral therapy since the original highly active antiretroviral therapy regimens were developed, there remain numerous important and pressing unmet needs that, if addressed, would substantially improve the quality of life and longevity of HIV-infected patients. The most achievable goals of antiretroviral (ARV) therapy in the near future are likely to be continued reduction in HIV-related morbidity and mortality; improved quality of life; and restoration and preservation of immune function: all of which are most effectively achieved through sustained suppression of HIV-1 RNA. The ability to achieve long-term viral load reduction will require new ARVs with few, manageable toxicities, and medications that are convenient to adhere to, with few drug interactions. This is particularly true for the large number of highly treatment-experienced patients in whom HIV has developed resistance to one or more ARVs. Development of therapies that allow convenient dosing schedules, that do not necessitate strict adherence to meal-related timing restrictions, and that remain active in the face of resistance mutations is paramount, and remains a significant unmet need. Of the large number of ARVs currently in development, this article focuses on three agents recently approved that have shown particular promise in addressing some of these unmet needs: the novel non-nucleoside reverse transcriptase inhibitor etravirine; the CCR5 antagonist maraviroc; and the integrase inhibitor raltegravir.",
author = "Graeme Moyle and Jose Gatell and Perno, {Carlo Federico} and Winai Ratanasuwan and Mauro Schechter and Christos Tsoukas",
year = "2008",
month = "6",
day = "1",
doi = "10.1089/apc.2007.0136",
language = "English",
volume = "22",
pages = "459--471",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection

AU - Moyle, Graeme

AU - Gatell, Jose

AU - Perno, Carlo Federico

AU - Ratanasuwan, Winai

AU - Schechter, Mauro

AU - Tsoukas, Christos

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Despite the myriad advances in antiretroviral therapy since the original highly active antiretroviral therapy regimens were developed, there remain numerous important and pressing unmet needs that, if addressed, would substantially improve the quality of life and longevity of HIV-infected patients. The most achievable goals of antiretroviral (ARV) therapy in the near future are likely to be continued reduction in HIV-related morbidity and mortality; improved quality of life; and restoration and preservation of immune function: all of which are most effectively achieved through sustained suppression of HIV-1 RNA. The ability to achieve long-term viral load reduction will require new ARVs with few, manageable toxicities, and medications that are convenient to adhere to, with few drug interactions. This is particularly true for the large number of highly treatment-experienced patients in whom HIV has developed resistance to one or more ARVs. Development of therapies that allow convenient dosing schedules, that do not necessitate strict adherence to meal-related timing restrictions, and that remain active in the face of resistance mutations is paramount, and remains a significant unmet need. Of the large number of ARVs currently in development, this article focuses on three agents recently approved that have shown particular promise in addressing some of these unmet needs: the novel non-nucleoside reverse transcriptase inhibitor etravirine; the CCR5 antagonist maraviroc; and the integrase inhibitor raltegravir.

AB - Despite the myriad advances in antiretroviral therapy since the original highly active antiretroviral therapy regimens were developed, there remain numerous important and pressing unmet needs that, if addressed, would substantially improve the quality of life and longevity of HIV-infected patients. The most achievable goals of antiretroviral (ARV) therapy in the near future are likely to be continued reduction in HIV-related morbidity and mortality; improved quality of life; and restoration and preservation of immune function: all of which are most effectively achieved through sustained suppression of HIV-1 RNA. The ability to achieve long-term viral load reduction will require new ARVs with few, manageable toxicities, and medications that are convenient to adhere to, with few drug interactions. This is particularly true for the large number of highly treatment-experienced patients in whom HIV has developed resistance to one or more ARVs. Development of therapies that allow convenient dosing schedules, that do not necessitate strict adherence to meal-related timing restrictions, and that remain active in the face of resistance mutations is paramount, and remains a significant unmet need. Of the large number of ARVs currently in development, this article focuses on three agents recently approved that have shown particular promise in addressing some of these unmet needs: the novel non-nucleoside reverse transcriptase inhibitor etravirine; the CCR5 antagonist maraviroc; and the integrase inhibitor raltegravir.

UR - http://www.scopus.com/inward/record.url?scp=48049107573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049107573&partnerID=8YFLogxK

U2 - 10.1089/apc.2007.0136

DO - 10.1089/apc.2007.0136

M3 - Article

C2 - 18479200

AN - SCOPUS:48049107573

VL - 22

SP - 459

EP - 471

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 6

ER -